• BCECF in Extracellular pH and Efferocytosis Research

  2026-10-10

  BCECF is a ratiometric, membrane-impermeant fluorescent pH indicator for studying extracellular and accessible compartmental acid–base changes. This overview places BCECF in the context of macrophage efferocytosis and neuropathic pain research, using Ruan et al. (2024) as a mechanistic case study while distinguishing established pathway findings from the still-unproven hypothesis that extracellular pH contributes to the observed ozone response.

• FLT3–TAZ Signaling in Blast-Phase CML

  2026-10-09

  Shin et al. repositioned FLT3 as both a prognostic marker and therapeutic vulnerability in blast-phase chronic myeloid leukemia (BP-CML), linking FLT3 expression to a JAK–STAT3–TAZ–TEAD–CD36 program associated with resistance to BCR::ABL1 tyrosine kinase inhibitors. The study combines resistant-cell models, longitudinal patient specimens, multi-omics, and xenograft evidence, while also showing why its findings should be viewed as a translational rationale rather than a clinical treatment recommendation.

• ECL Chemiluminescence: Evidence, Scope and Limits

  2026-10-09

  A source-grounded comparison of HRP-based immunoblot detection and amplification-free m6A analysis, explaining what the available evidence supports, what remains unvalidated, and where interpretation should stop.

• Rosemary-Root Lignans and Anti-Inflammatory Activity

  2026-10-08

  A January 2026 Fitoterapia study characterized eight lignans and four phenylpropanoids from Rosmarinus officinalis roots, including three previously unreported rosmarinicols. In an LPS-stimulated RAW264.7 macrophage model, six compounds reduced nitric oxide production, supporting rosemary roots as a source for further natural-product anti-inflammatory research while leaving mechanism, selectivity, and translational relevance unresolved.

• HyperScript™ Reverse Transcriptase for cDNA

  2026-10-08

  HyperScript™ Reverse Transcriptase is a genetically engineered M-MLV Reverse Transcriptase derivative described for RNA-to-cDNA conversion, including templates with complex secondary structure. The product dossier lists cDNA products up to 12.3 kb, but the supplied sources do not establish independent comparative performance or a validated clinical application.

• Ethacridine Lactate Monohydrate: Evidence and Scope

  2026-10-07

  Ethacridine lactate monohydrate is examined through an evidence-centered lens for biochemical and cellular research. This article connects its supplier-reported properties with the 2026 YAP–TEAD surface ectoderm study while distinguishing microbial control claims from biological interpretation.

• Thiazovivin Product Overview and Evidence Limits

  2026-10-07

  Thiazovivin (A5506) is a supplier-described ROCK inhibitor for conceptual stem cell research applications. No matched paper evidence was provided, so performance, mechanism, and applicability cannot be independently assessed here.

• Thiazovivin Product Overview and Evidence Limits

  2026-10-06

  Thiazovivin (SKU A5506) is a supplier-described ROCK inhibitor for stem cell research. No matched paper evidence was provided, so its reported research applications remain unverified within this overview.

• Lopinavir: What Cross-Viral Evidence Really Shows

  2026-10-06

  Lopinavir and ABT-378 are best understood through the relationship between molecular potency, cellular antiviral activity, and evidence provenance. This article examines HIV protease research and the MERS-CoV screening study without overstating what cross-viral findings demonstrate.

• Caspase-3 Fluorometric Assay Kit in Apoptosis Research

  2026-10-05

  A source-grounded overview of DEVD-dependent caspase activity detection, its relevance to apoptosis research, and how the Caspase-3 Fluorometric Assay Kit can be interpreted alongside orthogonal evidence. The discussion emphasizes the findings of Yao et al. in renal cell carcinoma, assay specificity, evidence strength, and applicability limits.

• HyperPFU™ High-Fidelity DNA Polymerase: Evidence

  2026-10-05

  Explore how HyperPFU high-fidelity DNA polymerase supports sequence-accurate analysis of difficult DNA, including GC-rich and long templates. This evidence-focused article connects polymerase fidelity with interpretation of recent base-editing research while defining important applicability limits.

• WZ4003: Interpreting NUAK1/2 Evidence

  2026-10-04

  WZ4003 is a NUAK1/2 inhibitor that connects kinase signaling with cell-cycle, migration, invasion, and tau biology. This evidence-led analysis focuses on how model differences and biomarker choice shape interpretation of its value in cancer research and neurodegeneration.

• LY364947 and TGF-β Signaling: Reading EMT Evidence

  2026-10-03

  Explore how LY364947, a TGF-β type I receptor kinase inhibitor, can frame mechanistic questions about Smad signaling, EMT, and the Wnt/β-catenin pathway. This evidence-focused analysis distinguishes established findings from hypotheses inspired by recent pancreatic cancer research.

• α-Bungarotoxin for Nicotinic Receptor Blockade

  2026-10-01

  Use α-Bungarotoxin to convert α7 receptor involvement from a correlation into a testable pharmacological hypothesis. This workflow connects receptor blockade with cholinergic signaling, necroptosis, inflammation, and trophoblast function while providing practical controls for neuroscience and translational assays.

• TH287 MTH1 Inhibitor for Radiosensitization

  2026-10-01

  TH287 converts MTH1-dependent nucleotide sanitization into a controllable cancer-cell stress model, with particular value in ionizing-radiation studies. A timing-focused workflow helps researchers examine oxidative DNA damage, apoptosis, cell-cycle arrest, and radiosensitization in castration-resistant prostate cancer models.

8703 records 1/581 page Next 12345 下5页 Last page